Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem.
Taiwan’s biotechnology sector was built around domestic health needs, including vaccines and drug manufacturing, but it is increasingly looking outward – to international partnerships, licensing, clinical development and a bigger role in the global biomedical ecosystem.
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell therapeutics emerging as the dark horse in what speakers at BIO Asia-Taiwan 2026 described as CAR T’s second revolution.
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that can demonstrate clinical differentiation, strong management teams and a clear path to commercialization.
Growing the international competitiveness of Taiwan’s biotech sector is one of six key strategies Taiwan’s government is heavily invested in, Taiwan President Tsai Ing-wen told attendees via video during the recent BIO Asia-Taiwan conference in Taipei.
Growing the international competitiveness of Taiwan’s biotech sector is one of six key strategies Taiwan’s government is heavily invested in, Taiwan President Tsai Ing-wen told attendees via video during the recent BIO Asia-Taiwan conference in Taipei.
Big pharma is increasingly turning to Taiwan to leverage the power of the country’s data and computing power as precision medicine takes center stage in drug development, speakers said during the recent BIO Asia-Taiwan conference in Taipei.
RSS
